{"organizations": [], "uuid": "c1b43b8a206fc67ce33526cd36da55a45111df0f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/12/globe-newswire-spring-bank-to-host-conference-call-to-discuss-fourth-quarter-and-fiscal-year-2017-results-on-wednesday-february-21.html", "country": "US", "domain_rank": 767, "title": "Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-02-12T16:00:00.000+02:00", "replies_count": 0, "uuid": "c1b43b8a206fc67ce33526cd36da55a45111df0f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/12/globe-newswire-spring-bank-to-host-conference-call-to-discuss-fourth-quarter-and-fiscal-year-2017-results-on-wednesday-february-21.html", "ord_in_thread": 0, "title": "Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "eastern time hopkinton", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "bank pharmaceuticals spring bank pharmaceuticals", "sentiment": "none"}, {"name": "spring bank pharmaceuticals, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Conference Call to be Held at 8:30am Eastern Time\nHOPKINTON, Mass., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will host a conference call to discuss its results for the fourth quarter and fiscal year ended December 31, 2017 and its 2018 development outlook at 8:30am Eastern Time on Wednesday, February 21, 2018.\nConference Call Details Date: Wednesday, February 21, 2018 Time: 8:30am Eastern Time US: 800-289-0517 International: 323-794-2423 Conference ID: 5789868 Webcast: http://public.viavid.com/index.php?id=128299 About Spring Bank Pharmaceuticals\nSpring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly SB 9200) for the treatment of viral diseases, including hepatitis B virus (HBV). Spring Bank Pharmaceuticals is also developing other SMNH product candidates, including SB 11285, the companyâ€™s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the ST imulator of IN terferon G enes, or STING, pathway. For more information, please visit www.springbankpharm.com\nContacts\nFor investor inquires:\nSpring Bank Pharmaceuticals, Inc.\nJonathan Freve\nChief Financial Officer\n(508) 473-5993\njfreve@springbankpharm.com\nLifeSci Advisors, LLC\nAndrew McDonald, Ph.D.\n(646) 597-6987\nandrew@lifesciadvisors.com\nMedia contact:\nLifeSci Public Relations\nMichael Tattory\n(646) 751-4362\nmtattory@lifescipublicrelations.com\nSource: Spring Bank Pharmaceuticals\nSource:Spring Bank Pharmaceuticals, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=RHoKnOwyyuxFZmb71mmLKTtRjkvy7bjNOJgCBFv8enFj9R7oin2iUVgLe7peZm_Mk9HNlr9fsYN_g7IBWIYVrY0l2C3txAYJb8VTpeuX7s3MJXagLQ4JV7f9vKqtmlW9D_a6bdknh18Tp9Gg3MCCKA==", "https://www.globenewswire.com/Tracker?data=H6y8_wIgDP7TblZ-1L_qgENHVWo2UjoiQYtaa9ZWn12g9mYC55LWb2ug3xjF2piKCAxupAc9tHtg2jKDMpJtF97GwzhfuUu_Wi8QjetueucYC_3Lo3-s_FJ9WRPskaVt", "https://www.globenewswire.com/Tracker?data=Kprp6ZvYoZoTDCrP7qwjJAUszZvvL_ymaWbIAwDRD2PM6qVQUUZPWMP8-wXuujwcBVgz3Qph1jmsDkvZSXhVVusanuh8QRPpZCI0ed80SVCTAcT4FlW4uXgTJ2r5FiYg", "https://www.globenewswire.com/NewsRoom/AttachmentNg/b1d96bdb-f242-47ec-91b4-9a871ca48a7c", "https://www.globenewswire.com/Tracker?data=vfSTWPSiZ4fH02TF1v6I0uU_CyeS_H7cpARTarCP_QTM2hvmlxOVhZWX4En6FrAigV0NPpuTqXLHFHl7o7syzCXOcyXwjgZlAMccSsAunLo=", "http://public.viavid.com/index.php?id=128299"], "published": "2018-02-12T16:00:00.000+02:00", "crawled": "2018-02-12T19:14:18.020+02:00", "highlightTitle": ""}